B
165.43
-0.02 (-0.01%)
| Previous Close | 165.45 |
| Open | 168.10 |
| Volume | 77,497 |
| Avg. Volume (3M) | 190,337 |
| Market Cap | 6,611,461,120 |
| Price / Earnings (Forward) | 227.27 |
| Price / Book | 8.57 |
| 52 Weeks Range | |
| Earnings Date | 12 May 2026 |
| Diluted EPS (TTM) | -1.36 |
| Total Debt/Equity (MRQ) | 0.37% |
| Current Ratio (MRQ) | 25.98 |
| Operating Cash Flow (TTM) | -29.23 M |
| Levered Free Cash Flow (TTM) | -13.42 M |
| Return on Assets (TTM) | -22.23% |
| Return on Equity (TTM) | -33.43% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Belite Bio, Inc | Bullish | Bullish |
AIStockmoo Score
0.5
| Analyst Consensus | 4.0 |
| Insider Activity | -2.5 |
| Price Volatility | -0.5 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | -2.0 |
| Average | 0.50 |
|
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 53.93% |
| % Held by Institutions | 0.75% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Darwin Global Management, Ltd. | 31 Dec 2025 | 3,027,704 |
| Western Standard Llc | 31 Dec 2025 | 60,026 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 266.00 (Cantor Fitzgerald, 60.79%) | Buy |
| Median | 200.50 (21.20%) | |
| Low | 195.00 (B of A Securities, 17.88%) | Buy |
| Average | 215.50 (30.27%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 166.53 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Cantor Fitzgerald | 03 Mar 2026 | 266.00 (60.79%) | Buy | 167.88 |
| HC Wainwright & Co. | 03 Mar 2026 | 200.00 (20.90%) | Buy | 167.88 |
| 28 Jan 2026 | 185.00 (11.83%) | Buy | 165.64 | |
| Morgan Stanley | 03 Mar 2026 | 201.00 (21.50%) | Buy | 167.88 |
| B of A Securities | 26 Jan 2026 | 195.00 (17.87%) | Buy | 162.47 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| CHEN WAN-SHAN | - | 181.17 | -1,100 | -199,287 |
| CHUANG HAO-YUAN | - | 181.17 | -6,200 | -1,123,254 |
| LIN YU-HSIN | - | 181.17 | -9,200 | -1,666,764 |
| MATA NATHAN L. | - | 168.76 | -1,000 | -168,760 |
| Aggregate Net Quantity | -17,500 | |||
| Aggregate Net Value ($) | -3,158,065 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 178.07 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| MATA NATHAN L. | Officer | 15 Apr 2026 | Automatic sell (-) | 1,000 | 168.76 | 168,760 |
| CHUANG HAO-YUAN | Officer | 09 Apr 2026 | Automatic sell (-) | 6,200 | 181.17 | 1,123,254 |
| LIN YU-HSIN | Officer | 09 Apr 2026 | Automatic sell (-) | 9,200 | 181.17 | 1,666,764 |
| CHEN WAN-SHAN | Director | 09 Apr 2026 | Automatic sell (-) | 1,100 | 181.17 | 199,287 |
| Date | Type | Details |
|---|---|---|
| 29 Jan 2026 | Announcement | Belite Bio Announces Participation at the 41st Asia-Pacific Academy of Ophthalmology Congress (APAO) |
| 27 Jan 2026 | Announcement | Belite Bio Completes Enrollment in the DRAGON II Clinical Trial of Tinlarebant for Stargardt Disease (STGD1) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |